News

Tessa Therapeutics (Tessa), an international clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for cancer, is a leading developer of personalized T cell therapies for solid tumors,

This marks the first approval of a long-acting treatment for opioid dependence in the EU. London’s King’s College National Addiction Centre director professor Sir John Strang, said: “Patients

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, which is under phase 3 development by GSK to treat anemia associated with chronic kidney disease (CKD). Inhibition of

The European approval for Luxturna is for the treatment of inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations in both adult and pediatric patients who have sufficient

Daurismo is claimed to be the first and only FDA-approved Hedgehog pathway inhibitor for AML. Daurismo, which is taken in combination with low-dose cytarabine (LDAC), has not been

The research collaboration brings together Evotec’s leading induced pluripotent stem cell (iPSC) platform and broad drug discovery capabilities with Immuneering’s unique artificial intelligence-driven drug discovery platform to accelerate

The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap

Through the acquisition of Avista, Cambrex will be adding early stage small molecule development and testing services to its capabilities. Avista, which is a portfolio company of Ampersand

LEO Pharma research vice president Thorsten Thormann said: “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin